Avant Technologies Evaluating Advanced Cells for Diabetes Therapy at 15th Annual EPITA Symposium
Rhea-AI Summary
Avant Technologies (OTCQB: AVAI) is presenting at the 15th EPITA Symposium in Igls, Austria, Jan 25-27, 2026, to evaluate advanced cells for potential use in a diabetes therapy.
The company said its representative, Dr. Eva Maria Lilli Brandtner, is assessing cells for combination with Avant's Cell-in-a-Box® microencapsulation platform, developed with SGAustria, which aims to protect transplanted insulin-producing cells without systemic immunosuppression.
The announcement emphasizes immunosuppression-free cell therapy approaches and Avant's goal to contribute to beta cell replacement for type 1 and insulin-dependent type 2 diabetes patients.
Positive
- None.
Negative
- None.
News Market Reaction – AVAI
On the day this news was published, AVAI declined NaN%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
The EPITA Symposium brings together global scientists, clinicians, and industry leaders to advance biological therapies for diabetes, including islet transplantation and beta cell replacement. EPITA stands as one of the world's flagship associations for networking on these critical topics, fostering collaboration to make therapies widely available.
Dr. Eva Maria Lilli Brandtner, Avant Technologies' expert representative, is assessing promising cells for inclusion with the company's Cell-in-a-Box® technology, developed in partnership with SGAustria. This clinically proven microencapsulation platform offers a safe, side-effect-free alternative to traditional immunosuppression, protecting transplanted insulin-producing cells from immune rejection without potential risks, such as tumor formation or infections that may be associated with gene editing and/or immunosuppression.
"While stem cell-derived beta cells undoubtedly represent a breakthrough in unlimited insulin sources, immune protection still remains a key challenge," said Dr. Brandtner. "Avant's Cell-in-a-Box® technology addresses this effectively, positioning us to contribute meaningfully to beta cell replacement therapies for type 1 and insulin-dependent type 2 diabetes patients worldwide."
Avant Technologies aims to strengthen its role in the community through this engagement, highlighting its innovative approach to enabling scalable, patient-friendly cell therapies.
About Avant Technologies, Inc.
Avant Technologies, Inc. is an emerging biotechnology company focused on identifying genetically modified cells lines, and through joint venture and licensing agreements developing innovative cell-based therapies.
About SGAustria Pte. Ltd.
SGAustria, based in
More information about Avant can be found at https://avanttechnologies.com
You can also follow us on social media at:
https://twitter.com/AvantTechAI
https://www.facebook.com/AvantTechAI
https://www.youtube.com/@AvantTechAI
Forward-Looking Statements
Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company's ability to raise capital on acceptable terms, if at all, the Company's successful development of its products and the integration into its existing products and the commercial acceptance of the Company's products. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date after the date of the press release.
Contact:
Avant Technologies, Inc.
info@avanttechnologies.com
Logo: https://mma.prnewswire.com/media/2840805/5733939/Avant_Technologies_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/avant-technologies-evaluating-advanced-cells-for-diabetes-therapy-at-15th-annual-epita-symposium-302669715.html
SOURCE Avant Technologies Inc.
FAQ
What is Avant Technologies announcing at EPITA Jan 25-27, 2026 (AVAI)?
How does Avant's Cell-in-a-Box® platform (AVAI) aim to help diabetes patients?
Who represents Avant Technologies at the 15th EPITA Symposium (AVAI)?
Does Avant claim its Cell-in-a-Box® eliminates risks like tumor formation or infections (AVAI)?
Will Avant's presentation at EPITA change clinical timelines for AVAI therapies?
Where and when did Avant evaluate cells for its diabetes therapy (AVAI)?
